KRAS
KRAS is a central oncogene and GTPase that acts as a binary switch for cell growth and survival. By cycling between active (GTP) and inactive (GDP) states, it controls the primary signaling lanes for cellular division; mutations that jam this switch in the "on" position are the foundational drivers of pancreatic, colorectal, and lung cancers.
Key Takeaways
- •KRAS is a molecular light switch that tells the cell when it is time to grow and divide.
- •In over 20% of all human cancers, this switch is broken and permanently stuck in the "on" position.
- •KRAS was considered "undruggable" for 40 years until the recent breakthrough of G12C covalent inhibitors.
- •The accumulation of KRAS mutations in healthy tissue is a hallmark of aging and DNA repair decline.
- •Metabolic health and low insulin levels can help reduce the upstream "pressure" on KRAS signaling pathways.
Basic Information
- Gene Symbol
- KRAS
- Full Name
- KRAS Proto-Oncogene, GTPase
- Also Known As
- p21K-RASNS3C-K-RAS
- Location
- 12p12.1
- Protein Type
- Small GTPase
- Protein Family
- RAS superfamily
Related Isoforms
The predominant isoform in human cells, essential for signaling.
An alternatively spliced form with lower expression levels.
Key SNPs
The most frequent KRAS mutation in pancreatic and colorectal cancers; historically undruggable.
Common in NSCLC; the first KRAS mutation to be successfully targeted with covalent inhibitors.
Common across GI cancers; associated with strong activation of survival pathways.
Overview
KRAS (KRAS Proto-Oncogene, GTPase) is a central relay in the cells communication system. It functions as a small GTPase, essentially a binary molecular switch that cycles between an inactive "off" state (bound to GDP) and an active "on" state (bound to GTP). When a growth factor binds to a receptor on the cell surface, KRAS is switched "on," triggering a cascade of signals that tell the cell to grow and divide.
In many cancers, somatic mutations in KRAS (most commonly at positions 12, 13, or 61) break the "off" switch. The protein remains permanently bound to GTP, sending a relentless signal for cell division that leads to tumor formation. This makes KRAS one of the most significant and historically challenging oncogenes in human medicine.
Conceptual Model
A simplified mental model for the pathway:
Mutations typically disable the GAP brake, leaving the growth engine at full throttle.
Core Health Impacts
- • Cell Proliferation: Master regulator of the MAPK/ERK pathway that drives cell cycle progression.
- • Survival Signaling: Co-activator of the PI3K/AKT/mTOR pathway to prevent programmed cell death.
- • Cytoskeletal Control: Regulates cell shape and the ability of cells to migrate and metastasize.
- • Metabolic Flux: Influences the metabolic reprogramming (Warburg effect) seen in cancer cells.
- • Growth Factor Relay: Acts as the primary intracellular relay for most cell-surface growth factor receptors.
Protein Domains
G Domain
The catalytic core that binds GTP/GDP and changes shape during activation.
P-Loop
The pocket holding the nucleotides; location of most oncogenic mutations.
HVR Region
Hypervariable region that undergoes lipid modification to anchor KRAS to the membrane.
Upstream Regulators
EGFR Activator
Epidermal Growth Factor Receptor; triggers RAS activation via recruitment of GEFs like SOS1.
SOS1 Activator
The primary Guanine Nucleotide Exchange Factor (GEF) that loads KRAS with GTP.
HER2 / ERBB2 Activator
Receptor tyrosine kinase that signals through the RAS/MAPK pathway.
SHP2 Activator
A protein phosphatase that acts as a scaffold for RAS activation; a major therapeutic target.
MET Activator
Hepatocyte Growth Factor receptor; can drive KRAS activation and drug resistance.
GAP Proteins Inhibitor
GTPase Activating Proteins that act as the brake, helping KRAS turn itself off.
Downstream Targets
BRAF Activates
Direct effector of KRAS; initiates the MAPK/ERK cascade for cell cycle progression.
PI3K (PIK3CA) Activates
KRAS directly activates PI3K, linking growth signals to the AKT/mTOR survival pathway.
RALGEF Activates
Activates RAL GTPases, which regulate membrane trafficking and contribute to metastasis.
MEK 1/2 Activates
Kinases downstream of BRAF that execute the MAPK program.
CRAF Activates
Another RAF isoform that KRAS can activate in specific tissue contexts.
TIAM1 Activates
A GEF for RAC1; mediates KRAS effects on the cytoskeleton and cell migration.
Role in Aging
While KRAS is primarily viewed through the lens of cancer, its biology is intimately tied to aging. The accumulation of somatic KRAS mutations is a natural byproduct of the aging process, reflecting the decline in DNA repair efficiency.
Mutational Burden
The probability of acquiring a KRAS mutation increases linearly with time, explaining why KRAS cancers are diseases of the elderly.
Clonal Evolution
Aging creates a selection pressure in tissues. Cells with KRAS mutations gain a fitness advantage and expand clonally.
Inflammaging
Chronic low-grade inflammation provides the second hit needed for a KRAS-mutated cell to progress toward a tumor.
Metabolic Support
The aging metabolic environment (e.g., higher insulin levels) may specifically favor the growth of KRAS-driven tumors.
Senescence Bypass
While weak signals trigger senescence, strong KRAS mutations are often the event that allows a cell to bypass this aging barrier.
Proteostatic Drift
Declining chaperone and proteasome activity in aging makes it harder for the cell to manage mutant RAS protein levels.
Disorders & Diseases
Pancreatic Cancer (PDAC)
KRAS mutations (especially G12D) are present in over 90% of cases, acting as the initiating driver event.
Colorectal Cancer (CRC)
Found in ~40% of cases. KRAS status is a mandatory biomarker for anti-EGFR therapy eligibility.
Non-Small Cell Lung Cancer
The G12C mutation is prevalent in smokers and is the primary target for new covalent inhibitors.
RASopathies
Rare germline mutations in KRAS can cause developmental syndromes like Noonan syndrome.
Interventions
Supplements
Investigated for potential to modulate RAS/MAPK signaling, though bioavailability is a challenge.
May influence NRF2-mediated detoxification which can be hijacked by KRAS-driven tumors.
Studied for anti-inflammatory effects that may intersect with oncogenic signaling environments.
Lifestyle
Tobacco smoke is a primary driver of the KRAS G12C mutations found in lung cancer.
Insulin and IGF-1 can provide extra upstream activation pressure to KRAS-driven pathways.
Crucial for KRAS-associated cancers where early detection significantly changes outcomes.
Medicines
First FDA-approved KRAS G12C covalent inhibitor for advanced NSCLC.
Covalent G12C inhibitor with high CNS penetration, used in lung and colorectal cancers.
KRAS status is a mandatory biomarker; mutations typically confer resistance to these drugs.
Used to block the downstream MAPK pathway, often in combination with other targeted therapies.
Lab Tests & Biomarkers
Mutation Testing
Next-Generation Sequencing to identify specific somatic KRAS alleles.
Detecting KRAS mutations in blood for tracking tumor progression.
Clinical Diagnostics
KRAS status dictates candidacy for cetuximab and panitumumab in CRC.
Required for treatment with G12C-specific covalent inhibitors.
Hormonal Interactions
Insulin Metabolic Activator
Signals through the PI3K/AKT axis, which cross-talks extensively with KRAS effectors.
Growth Hormone Indirect Driver
Elevates IGF-1 levels, which can stimulate upstream pathways leading to KRAS activation.
Estrogen Modulator
Can influence the expression of growth factor receptors that signal through KRAS.
Deep Dive
Network Diagrams
The KRAS GTP/GDP Binary Switch
KRAS Feedback and Resistance
The GTPase Cycle: How a Molecular Switch Fails
To understand KRAS, one must understand the GTPase cycle. KRAS acts like a light switch with a built-in timer. You turn it “on” (GTP), and after a set time, it turns itself “off” (GDP).
- The GEF (SOS1): Growth factor receptors recruit SOS1, which physically “pries” open the KRAS protein, allowing it to drop its GDP and pick up a fresh GTP. This is the “on” event.
- The GAP (Brake): KRAS is a weak enzyme; it needs a helper protein called a GAP (GTPase Activating Protein) to turn itself off. Most oncogenic mutations (like G12D or G12C) change the shape of the protein so that the GAP can no longer fit. The switch is now permanently taped in the “on” position.
The “Hydra” of Signaling and Drug Resistance
For 40 years, KRAS was considered “undruggable.” Even with the breakthrough of G12C inhibitors, the cell often finds a way to bypass the blockade through complex feedback loops.
- Adaptive Resistance: When you block KRAS, the cell often “senses” the loss of signal and reacts by upregulating upstream receptors (like EGFR). This floods the cell with “on” signals, trying to overcome the drug.
- Alternative Pathways: KRAS is a hub. If one downstream path (like MAPK) is blocked, the signal may “overflow” into another path (like PI3K), allowing the tumor to continue growing through an alternative route.
Somatic Evolution and the Aging Clock
KRAS mutations are not usually inherited; they are somatic, meaning they are acquired during your lifetime. They are a classic example of “cellular aging.”
As we age, our DNA repair mechanisms become less efficient, and our tissues undergo thousands of rounds of division. Each round is an opportunity for a random mistake in the KRAS gene. While most of these mutated cells are killed by the immune system or enter senescence, eventually one may survive and expand, leading to the late-life onset of the cancers most associated with KRAS.
KRAS and Precision Medicine
Status is Mandatory. KRAS testing is a standard of care in oncology, as it determines which treatments will be effective.
Molecular Dynamics. KRAS is not a single problem; different mutations (G12C vs G12D) require different therapeutic strategies.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The foundational paper that identified KRAS as a major human oncogene.
The landmark trial proving that KRAS could be targeted by small molecules.
Review on how the accumulation of somatic mutations like KRAS is a hallmark of aging.
Shows how the aging environment shapes the progression of KRAS tumors.